Linked Life Data

17625972

Source:http://linkedlifedata.com/resource/pubmed/id/17625972

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2007-8-16
pubmed:abstractText
Novel anti-HIV agents that target different stages of the human immunodeficiency virus type 1 (HIV-1) replication cycle are now in clinical trials and have signs of improving our ability to manage HIV-1. This chapter, and the Conference presentation, dealt with the challenges encountered in realizing the optimal benefits of the newer therapeutics to individuals with AIDS and HIV-1 infection receiving highly active antiretroviral therapy (HAART). Emphasis was on the G-protein-coupled seven-transmembrane chemokine receptor, CCR5, as a potentially new therapeutic target and experience with novel CCR5 inhibitors, and the promise from further advancement through structural and molecular analysis of CCR5 inhibitor-CCR5 interactions. The promise in some of the newer protease inhibitors was also discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1472-9792
pubmed:author
pubmed:issnType
Print
pubmed:volume
87 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S31-4
pubmed:dateRevised
2009-4-22
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Development of therapeutics for AIDS: structure-based molecular targeting.
pubmed:affiliation
Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA. maedak@mail.nih.gov
pubmed:publicationType
Journal Article, Review